What is CovalX?
CovalX is a prominent provider of advanced solutions for the characterization of therapeutic proteins. The company specializes in critical areas such as epitope mapping and protein interaction analysis, leveraging a comprehensive suite of mass spectrometry techniques including XL-MS, HDX-MS, and mAb characterization. These services are indispensable for clients within the life sciences industry, enabling scientists to accelerate breakthrough discoveries. CovalX's commitment to quality and its global presence serve a distinguished clientele in the pharmaceutical and biotechnology sectors.
How much funding has CovalX raised?
CovalX has raised a total of $89K across 1 funding round:
Debt
$89K
Debt (2021): $89K with participation from PPP
What's next for CovalX?
Operating at a significant Series B/C stage, CovalX's recent acquisition of substantial expansion capital signals a strategic push for accelerated growth and market penetration. This financing is expected to fuel further development of their innovative protein characterization technologies and potentially broaden their service offerings. The company is poised to enhance its capabilities in supporting pharmaceutical and biotechnology firms, reinforcing its role in advancing human health through scientific innovation.
See full CovalX company page
